BIO-TECHNE Corp Interest Expense
BIO-TECHNE Corp (TECH) reported Interest Expense of $4.00 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-06.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-06
- BIO-TECHNE Corp interest expense for the quarter ending 2024-03-31 was $4.00M, a 192.98% increase year-over-year.
- BIO-TECHNE Corp interest expense for the quarter ending 2023-12-31 was $4.33M, a 83.74% increase year-over-year.
- BIO-TECHNE Corp interest expense for the quarter ending 2023-09-30 was $4.89M, a 29.10% increase year-over-year.
- BIO-TECHNE Corp interest expense for the quarter ending 2023-06-30 was $3.70M, a 47.78% increase year-over-year.
- BIO-TECHNE Corp interest expense for fiscal 2023 was $11.21M, a 0.83% decline from fiscal 2022.
- BIO-TECHNE Corp interest expense for fiscal 2022 was $11.31M, a 18.94% decline from fiscal 2021.
- BIO-TECHNE Corp interest expense for fiscal 2021 was $13.95M, a 27.32% decline from fiscal 2020.
- BIO-TECHNE Corp interest expense for fiscal 2020 was $19.20M, a 11.55% decline from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2024-03-31 | $4.00M 10-Q · filed 2024-05-06 | $8.33M derived: sum of 2 quarters · filed 2024-05-06 | $13.23M 10-Q · filed 2024-05-06 | $16.93M derived: sum of 4 quarters · filed 2024-05-06 | |||
| 2023-12-31 | $4.33M 10-Q · filed 2024-02-07 | $9.22M 10-Q · filed 2024-02-07 | $12.92M derived: sum of 3 quarters · filed 2024-02-07 | $14.29M derived: sum of 4 quarters · filed 2024-05-06 | |||
| 2023-09-30 | $4.89M 10-Q · filed 2023-11-07 | $8.60M derived: sum of 2 quarters · filed 2023-11-07 | $9.96M derived: sum of 3 quarters · filed 2024-05-06 | $12.32M derived: sum of 4 quarters · filed 2024-05-06 | |||
| 2023-06-30 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $5.07M derived: sum of 2 quarters · filed 2024-05-06 | $7.42M derived: sum of 3 quarters · filed 2024-05-06 | $11.21M 10-K · filed 2023-08-23 | |||
| 2023-03-31 | $1.37M 10-Q · filed 2024-05-06 | $3.72M derived: sum of 2 quarters · filed 2024-05-06 | $7.51M 10-Q · filed 2024-05-06 | $10.02M derived: sum of 4 quarters · filed 2024-05-06 | |||
| 2022-12-31 | $2.36M 10-Q · filed 2024-02-07 | $6.15M 10-Q · filed 2024-02-07 | $8.65M derived: sum of 3 quarters · filed 2024-02-07 | $11.14M derived: sum of 4 quarters · filed 2024-02-07 | |||
| 2022-09-30 | $3.79M 10-Q · filed 2023-11-07 | $6.29M derived: sum of 2 quarters · filed 2023-11-07 | $8.79M derived: sum of 3 quarters · filed 2023-11-07 | $11.69M derived: sum of 4 quarters · filed 2023-11-07 | |||
| 2022-06-30 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $5.00M derived: sum of 2 quarters · filed 2023-08-23 | $7.90M derived: sum of 3 quarters · filed 2023-08-23 | $11.31M 10-K · filed 2023-08-23 | |||
| 2022-03-31 | $2.49M 10-Q · filed 2023-05-08 | $5.39M derived: sum of 2 quarters · filed 2023-05-08 | $8.80M 10-Q · filed 2023-05-08 | $12.10M derived: sum of 4 quarters · filed 2023-08-23 | |||
| 2021-12-31 | $2.90M 10-Q · filed 2023-02-07 | $6.31M 10-Q · filed 2023-02-07 | $9.60M derived: sum of 3 quarters · filed 2023-08-23 | $12.26M derived: sum of 4 quarters · filed 2023-08-23 | |||
| 2021-09-30 | $3.41M 10-Q · filed 2022-11-07 | $6.70M derived: sum of 2 quarters · filed 2023-08-23 | $9.36M derived: sum of 3 quarters · filed 2023-08-23 | $12.95M derived: sum of 4 quarters · filed 2023-08-23 | |||
| 2021-06-30 | $3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $5.95M derived: sum of 2 quarters · filed 2023-08-23 | $9.54M derived: sum of 3 quarters · filed 2023-08-23 | $13.95M 10-K · filed 2023-08-23 | |||
| 2021-03-31 | $2.66M 10-Q · filed 2022-05-09 | $6.25M derived: sum of 2 quarters · filed 2022-05-09 | $10.66M 10-Q · filed 2022-05-09 | $15.28M derived: sum of 4 quarters · filed 2022-08-24 | |||
| 2020-12-31 | $3.58M 10-Q · filed 2022-02-07 | $8.00M 10-Q · filed 2022-02-07 | $12.62M derived: sum of 3 quarters · filed 2022-08-24 | $17.10M derived: sum of 4 quarters · filed 2022-08-24 | |||
| 2020-09-30 | $4.42M 10-Q · filed 2021-11-08 | $9.03M derived: sum of 2 quarters · filed 2022-08-24 | $13.52M derived: sum of 3 quarters · filed 2022-08-24 | $18.39M derived: sum of 4 quarters · filed 2022-08-24 | |||
| 2020-06-30 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-24 | $9.10M derived: sum of 2 quarters · filed 2022-08-24 | $13.97M derived: sum of 3 quarters · filed 2022-08-24 | $19.20M 10-K · filed 2022-08-24 | |||
| 2020-03-31 | $4.49M 10-Q · filed 2021-05-07 | $9.36M derived: sum of 2 quarters · filed 2021-05-07 | $14.58M 10-Q · filed 2021-05-07 | $20.18M derived: sum of 4 quarters · filed 2021-08-25 | |||
| 2019-12-31 | $4.87M 10-Q · filed 2021-02-08 | $10.09M 10-Q · filed 2021-02-08 | $15.69M derived: sum of 3 quarters · filed 2021-08-25 | $20.80M derived: sum of 4 quarters · filed 2021-08-25 | |||
| 2019-09-30 | $5.22M 10-Q · filed 2020-11-09 | $10.82M derived: sum of 2 quarters · filed 2021-08-25 | $15.93M derived: sum of 3 quarters · filed 2021-08-25 | $21.69M derived: sum of 4 quarters · filed 2021-08-25 | |||
| 2019-06-30 | $5.59M derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-25 | $10.71M derived: sum of 2 quarters · filed 2021-08-25 | $16.47M derived: sum of 3 quarters · filed 2021-08-25 | $21.70M 10-K · filed 2021-08-25 | |||
| 2019-03-31 | $5.11M 10-Q · filed 2020-05-11 | $10.87M derived: sum of 2 quarters · filed 2020-05-11 | $16.11M 10-Q · filed 2020-05-11 | $19.16M derived: sum of 4 quarters · filed 2020-08-26 | |||
| 2018-12-31 | $5.76M 10-Q · filed 2020-02-06 | $11.00M 10-Q · filed 2020-02-06 | $14.05M derived: sum of 3 quarters · filed 2020-08-26 | $16.61M derived: sum of 4 quarters · filed 2020-08-26 | |||
| 2018-09-30 | $5.24M 10-Q · filed 2019-11-06 | $8.29M derived: sum of 2 quarters · filed 2020-08-26 | $10.85M derived: sum of 3 quarters · filed 2020-08-26 | $13.18M derived: sum of 4 quarters · filed 2020-08-26 | |||
| 2018-06-30 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-26 | $5.61M derived: sum of 2 quarters · filed 2020-08-26 | $7.94M derived: sum of 3 quarters · filed 2020-08-26 | $10.19M 10-K · filed 2020-08-26 | |||
| 2018-03-31 | $2.56M 10-Q · filed 2019-05-07 | $4.89M derived: sum of 2 quarters · filed 2019-05-07 | $7.13M 10-Q · filed 2019-05-07 | $9.06M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-12-31 | $2.33M 10-Q · filed 2019-02-07 | $4.57M 10-Q · filed 2019-02-07 | $6.50M derived: sum of 3 quarters · filed 2019-11-06 | $8.61M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-09-30 | $2.24M 10-Q · filed 2018-11-07 | $4.17M derived: sum of 2 quarters · filed 2019-11-06 | $6.28M derived: sum of 3 quarters · filed 2019-11-06 | $8.20M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-06-30 | $1.93M derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-11-06 | $4.04M derived: sum of 2 quarters · filed 2019-11-06 | $5.96M derived: sum of 3 quarters · filed 2019-11-06 | $7.36M 10-K/A · filed 2019-11-06 | |||
| 2017-03-31 | $2.11M 10-Q · filed 2018-05-09 | $2.02M 10-Q · filed 2017-05-10 | $4.03M derived: sum of 2 quarters · filed 2018-05-09 | $5.43M 10-Q · filed 2018-05-09 | $5.20M 10-Q · filed 2017-05-10 | $5.86M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2016-12-31 | $1.92M 10-Q · filed 2018-02-08 | $1.83M 10-Q · filed 2017-02-09 | $3.32M 10-Q · filed 2018-02-08 | $3.18M 10-Q · filed 2017-02-09 | $3.75M derived: sum of 3 quarters · filed 2018-08-27 | $4.20M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2016-09-30 | $1.40M 10-Q · filed 2017-11-09 | $1.34M 10-Q · filed 2016-11-09 | $1.83M derived: sum of 2 quarters · filed 2018-08-27 | $2.28M derived: sum of 3 quarters · filed 2018-08-27 | $2.68M derived: sum of 4 quarters · filed 2018-08-27 | ||
| 2016-06-30 | $433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-27 | $881.00K derived: sum of 2 quarters · filed 2018-08-27 | $1.28M derived: sum of 3 quarters · filed 2018-08-27 | $1.75M 10-K · filed 2018-08-27 | |||
| 2016-03-31 | $448.00K 10-Q · filed 2017-05-10 | $848.00K derived: sum of 2 quarters · filed 2017-05-10 | $1.31M 10-Q · filed 2017-05-10 | $1.69M derived: sum of 4 quarters · filed 2017-09-07 | |||
| 2015-12-31 | $400.00K 10-Q · filed 2017-02-09 | $851.00K 10-Q · filed 2017-02-09 | $1.24M derived: sum of 3 quarters · filed 2017-09-07 | $1.65M derived: sum of 4 quarters · filed 2017-09-07 | |||
| 2015-09-30 | $451.00K 10-Q · filed 2016-11-09 | $839.00K derived: sum of 2 quarters · filed 2017-09-07 | $1.25M derived: sum of 3 quarters · filed 2017-09-07 | $1.69M derived: sum of 4 quarters · filed 2017-09-07 | |||
| 2015-06-30 | $388.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | $802.00K derived: sum of 2 quarters · filed 2017-09-07 | $1.24M derived: sum of 3 quarters · filed 2017-09-07 | $1.54M 10-K · filed 2017-09-07 | |||
| 2015-03-31 | $414.00K 10-Q · filed 2016-05-10 | $851.00K derived: sum of 2 quarters · filed 2016-05-10 | $1.16M 10-Q · filed 2016-05-10 | ||||
| 2014-12-31 | $437.00K 10-Q · filed 2016-02-09 | $748.00K 10-Q · filed 2016-02-09 | |||||
| 2014-09-30 | $311.00K 10-Q · filed 2015-11-09 | ||||||
| 2014-06-30 | $0.00 10-K · filed 2016-08-29 | ||||||
| 2013-12-31 | $0.00 10-Q · filed 2015-02-09 | $0.00 10-Q · filed 2015-02-09 | |||||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-10 | ||||||
| 2013-06-30 | $0.00 10-K · filed 2015-08-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |